Elevance Health, INC

Elevance Health reported strong second quarter 2026 results, exceeding expectations and leading to an increase in full-year guidance for both earnings per share and operating cash flow.

Elevance Health reaffirms its 2026 earnings per diluted share guidance and benefit expense ratio guidance during investor meetings.

Elevance Health's annual shareholder meeting saw the election of directors, approval of executive compensation, and ratification of its auditor, with one shareholder proposal failing to pass.

Elevance Health reported strong first quarter 2026 results, exceeding expectations and leading to an increase in full-year adjusted EPS guidance.

Elevance Health, Inc. announced that the Centers for Medicare & Medicaid Services intends to impose sanctions suspending new Medicare Advantage enrollments and certain communications due to past data submission noncompliance.

Elevance Health announced key executive leadership changes and reaffirmed its full-year 2026 financial guidance, including adjusted earnings of at least $25.50 per diluted share.

Elevance Health reports a 16.1% decrease in net income for Q2 2026 compared to the prior year, driven by increased medical costs and strategic investments, despite a slight rise in total operating revenue.

Elevance Health reported a 1.5% increase in total operating revenue for Q1 2026, reaching $49.5 billion, though net income saw a 19.2% decrease to $1.76 billion.

Elevance Health reported strong third-quarter revenue and EPS growth, yet nine-month net income and operating cash flow declined amidst rising medical costs and a significant litigation settlement.

Elevance Health reported a decrease in net income and diluted earnings per share for the second quarter and first half of 2025, primarily due to higher medical cost trends and increased financial instrument losses, despite significant operating revenue growth.

Elevance Health's Q1 2025 results show revenue growth driven by premium increases and strategic acquisitions, though net income saw a slight decrease.

Elevance Health's Q3 2024 results show a mix of revenue growth and profit challenges, influenced by Medicaid membership changes and strategic business adjustments.

Elevance Health's 2025 annual report shows revenue growth driven by acquisitions and Medicare Advantage, but net income and cash flow declined due to higher medical costs and a significant legal settlement.

Elevance Health showcases a resilient performance in 2024, marked by revenue growth and strategic acquisitions, while addressing challenges from Medicaid redeterminations and adjustments in Medicare Advantage Star Ratings.

Elevance Health's 2023 annual report highlights a year of strategic realignment, solid membership, and revenue growth, despite challenges in the Medicaid sector.

Ramiro G Peru, a Director of Elevance Health, Inc., purchased 1,000 shares of common stock on July 17, 2026 for $366.05 per share.

Gail Boudreaux, President and CEO and a Director of Elevance Health, Inc., purchased 2,725 shares of common stock on July 17, 2026.

Elevance Health Director Robert L. Dixon Jr. sold 151 shares of common stock at a price of $401.77 per share.

Ronald W. Penczek, CAO & Controller of Elevance Health, Inc., reported transactions involving the acquisition and disposition of company common stock and employee stock options on May 19, 2026.

Director Deanna D. Strable-Soethout acquired 563 deferred stock units as part of the Elevance Health Board of Directors Compensation Program.

Director Antonio F. Neri acquired 563 deferred stock units as part of the Elevance Health Board of Directors Compensation Program.

Elevance Health reported 13% operating revenue growth to $197.6 billion in 2025, alongside strategic advancements in its whole health approach and corporate governance.

Elevance Health announces its annual shareholder meeting to be held virtually on May 14, 2025, covering director elections, executive compensation, auditor ratification, and a DEI report proposal.

Elevance Health announces its annual shareholder meeting to be held virtually on May 14, 2025, with key proposals including director elections and executive compensation.

Elevance Health's proxy statement outlines the company's 2024 performance, 2025 growth plans, and corporate governance practices.

Elevance Health files a supplement to its proxy statement to correct an error in the Summary Compensation Table, which omitted a one-time cash award to the CFO, Mark B. Kaye.

Elevance Health, Inc. has filed a definitive proxy statement with the SEC.

Vanguard Capital Management has filed a Schedule 13G reporting a 7.13% beneficial ownership stake in Elevance Health Inc.

The Vanguard Group filed an Amendment No. 11 to Schedule 13G for Elevance Health Inc., reporting 0% beneficial ownership due to an internal realignment.

The Vanguard Group has filed an amended Schedule 13G, reporting a 10.13% beneficial ownership stake in Elevance Health Inc., held for passive investment purposes.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 7.8% beneficial ownership stake in Elevance Health, Inc. as of March 31, 2025.